You are here

MS Drug Linked to Deadly Brain Infection

Finger of suspicion points to Ocrevus, but Tysabri may be the real culprit

A patient in Germany treated with the new multiple sclerosis (MS) drug ocrelizumab (Ocrevus, Roche) has been diagnosed with progressive multifocal leukoencephalopathy (PML), a potentially deadly brain infection, after switching from natalizumab (Tysabri, Biogen) following three years of treatment, according to a Reuters report. The patient received a single dose of ocrelizumab in February.

According to Roche, however, the case of PML was reported as a carry-over from natalizumab by the patient’s attending physician. The patient had previously tested positive for John Cunningham virus, a common virus that is normally harmless but can lead to PML in MS patients with weakened immune systems.

Dozens of patients receiving treatment with natalizumab have been diagnosed with PML. Use of the drug was temporarily halted in 2005, but was resumed after patients for whom the medication was effective demanded its return and regulators added restrictions to its use.

Roche has said no cases of PML emerged during its trials of ocrelizumab, but the company included warnings to patients taking the medication that there was a risk they could develop the disease.

Ocrelizumab was approved by the FDA in March 2017. It is the only disease-modifying therapy indicated for the primary progressive form of MS, Roche said. Ocrelizumab is a monoclonal antibody designed to target CD20-positive B cells, a specific type of immune cell thought to be a key contributor to myelin and axonal damage.

Natalizumab, another immunomodulator, was approved for use in MS patients in 2004.

Sources: Reuters; May 25, 2017; and BioSpace; May 25, 2017.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks